CAMPBELL, Calif., April 27, 2020 /PRNewswire/ -- BioPharmX
Corporation (NYSE American: BPMX) ("BioPharmX")
today announced that the date of its special stockholders' meeting
to consider and vote on the proposed merger of BioPharmX with
Timber Pharmaceuticals LLC ("Timber") and related matters has been
changed. The meeting will now be held on Wednesday, May 13, 2020 at 10:00 AM
eastern time.
Further, due to the COVID-19 pandemic, BioPharmX has determined
that for the health and well-being of its stockholders, BioPharmX's
special meeting of stockholders to consider and vote upon the
proposed merger and related matters will be a virtual meeting
conducted exclusively via live audiocast at
https://www.viewproxy.com/BioPharmXCorp/2020. There will not be a
physical location for the special meeting, and you will not be able
to attend the meeting in person.
Where to find additional information about the Special
Stockholders Meeting, the proposed Merger and related
matters
On February 20, 2020, BioPharmX
filed a Registration Statement on Form S-4 with the U.S. Securities
and Exchange Commission ("SEC") containing a prospectus and a proxy
statement of BioPharmX concerning the proposed merger between
BioPharmX and Timber. The registration statement was declared
effective by the SEC on March 30,
2020 and the proxy statement describing the merger and
related matters was mailed to BioPharmX stockholders on or about
April 6, 2020. Subsequently, on
April 27, 2020, BioPharmX filed a
supplement to its proxy statement describing certain changes to the
terms of the merger and related matters from that described in the
original proxy statement. The supplement is expected to be mailed
to BioPharmX stockholders on or about April
28, 2020 and the special stockholders meeting of BioPharmX
to consider and vote upon the merger and the related matters
described in the proxy statement and the supplement is now
scheduled to be held on Wednesday, May 13,
2020 at 10:00 AM eastern
time.
INVESTORS AND SECURITY HOLDERS OF BIOPHARMX ARE URGED TO READ
THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY
CONTAIN IMPORTANT INFORMATION ABOUT BIOPHARMX, TIMBER, THE PROPOSED
MERGER, AND RELATED MATTERS.
The proxy statement/prospectus, the supplement, and any other
documents filed by BioPharmX with the SEC, may be obtained free of
charge at the SEC website at www.sec.gov. In addition, investors
and security holders may obtain free copies of the documents filed
with the SEC by BioPharmX by directing a written request to:
BioPharmX Corporation, 900 E. Hamilton Avenue, Suite 100,
Campbell, CA 95008 or by
downloading the materials from the Investor Page of the BioPharmX
website, www.BioPharmX.com. BioPharmX security holders are urged to
read the proxy statement/prospectus and the supplement before
making any voting or investment decision with respect to the
proposed merger.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE American: BPMX) is a specialty
pharmaceutical company focused on developing prescription
products utilizing its proprietary HyantX Topical Delivery System
for dermatology indications. To learn more about BioPharmX, visit
www.BioPharmX.com.
About Timber Pharmaceuticals LLC
Timber Pharmaceuticals is a privately held biopharmaceutical
company focused on the development and commercialization of
treatments for orphan dermatologic diseases. The company's
investigational therapies have proven mechanisms-of-action backed
by decades of clinical experience and well-established CMC
(chemistry, manufacturing and control) and safety profiles. Timber
is initially focused on developing non-systemic treatments for rare
dermatologic diseases including congenital ichthyosis (CI),
tuberous sclerosis complex (TSC), and localized scleroderma. For
more information, visit https://www.timberpharma.com/.
Forward-Looking Statements
This press release contains forward-looking statements based
upon BioPharmX's and Timber's current expectations. This
communication contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are identified by terminology such as
"may," "should," "expects," "plans," "anticipates," "could,"
"intends," "target," "projects," "contemplates," "believes,"
"estimates," "predicts," "potential" or "continue" or the negative
of these terms or other similar words. These statements are only
predictions. BioPharmX and Timber have based these forward-looking
statements largely on their then-current expectations and
projections about future events, as well as the beliefs and
assumptions of management. Forward-looking statements are subject
to a number of risks and uncertainties, many of which involve
factors or circumstances that are beyond each of BioPharmX's and
Timber's control, and actual results could differ materially from
those stated or implied in forward-looking statements due to a
number of factors, including but not limited to: (i) risks
associated with BioPharmX's ability to obtain the stockholder
approval required to consummate the proposed merger transaction and
related matters and the timing of the closing of the proposed
merger transaction, including the risks that a condition to closing
would not be satisfied within the expected timeframe or at all or
that the closing of the proposed merger transaction will not occur;
(ii) the outcome of any legal proceedings that may be instituted
against the parties and others related to the merger agreement;
(iii) whether the NYSE American will continue to list the common
shares of BioPharmX following the merger, (iv) the occurrence of
any event, change or other circumstance or condition that could
give rise to the termination of the merger agreement, (v)
unanticipated difficulties or expenditures relating to the proposed
merger transaction, the response of business partners and
competitors to the announcement of the proposed merger transaction,
and/or potential difficulties in employee retention as a result of
the announcement and pendency of the proposed merger transaction;
(vi) whether the combined business of Timber and BioPharmX will be
successful, and (vii) those risks detailed in BioPharmX's most
recent Annual Report on Form 10-K for the fiscal year ended
January 31, 2020 and subsequent
reports filed with the SEC, as well as other documents that may be
filed by BioPharmX from time to time with the SEC (including the
proxy statement/prospectus and the supplement). Accordingly, you
should not rely upon forward-looking statements as predictions of
future events. Neither BioPharmX nor Timber can assure you that the
events and circumstances reflected in the forward-looking
statements will be achieved or occur, and actual results could
differ materially from those projected in the forward-looking
statements. The forward-looking statements made in this
communication relate only to events as of the date on which the
statements are made. Except as required by applicable law or
regulation, BioPharmX and Timber undertake no obligation to update
any forward-looking statement to reflect events or circumstances
after the date on which the statement is made or to reflect the
occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biopharmx-corporation-announces-that-its-special-stockholders-meeting-will-now-be-held-on-wednesday-may-13-2020-at-1000-am-eastern-time-301047762.html
SOURCE BioPharmX Corporation